1. Home
  2. LNG vs INSM Comparison

LNG vs INSM Comparison

Compare LNG & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cheniere Energy Inc.

LNG

Cheniere Energy Inc.

HOLD

Current Price

$192.19

Market Cap

46.4B

Sector

Utilities

ML Signal

HOLD

Logo Insmed Incorporated

INSM

Insmed Incorporated

HOLD

Current Price

$166.07

Market Cap

41.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LNG
INSM
Founded
1983
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Oil/Gas Transmission
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
46.4B
41.2B
IPO Year
1997
2000

Fundamental Metrics

Financial Performance
Metric
LNG
INSM
Price
$192.19
$166.07
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
13
21
Target Price
$265.46
$188.05
AVG Volume (30 Days)
2.2M
3.1M
Earning Date
10-30-2025
10-30-2025
Dividend Yield
1.17%
N/A
EPS Growth
14.15
N/A
EPS
17.92
N/A
Revenue
$18,937,000,000.00
$447,022,000.00
Revenue This Year
$30.57
$43.10
Revenue Next Year
$13.71
$128.25
P/E Ratio
$10.62
N/A
Revenue Growth
21.55
30.34
52 Week Low
$186.20
$60.40
52 Week High
$257.65
$212.75

Technical Indicators

Market Signals
Indicator
LNG
INSM
Relative Strength Index (RSI) 29.60 29.47
Support Level $186.20 $192.50
Resistance Level $209.49 $205.23
Average True Range (ATR) 4.17 7.18
MACD -0.82 -3.68
Stochastic Oscillator 23.89 9.25

Price Performance

Historical Comparison
LNG
INSM

About LNG Cheniere Energy Inc.

Cheniere Energy is a liquified natural gas, or LNG, producer with two facilities in Corpus Christi, Texas and Sabine Pass, Louisiana. It generates most of its revenue through long-term contracts with customers on a fixed and variable fee payout structure. It also generates revenue by selling uncontracted LNG to customers on a short or one-time basis. A subsidiary, Cheniere Energy Partners, owns the Sabine Pass facility and trades as a master limited partnership.

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

Share on Social Networks: